

**POSTER PRESENTATION**

**Open Access**

# Recent advances in adoptive cancer immunotherapy in china

Juhua Zhou

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

## Background

Cytokine-induced killer (CIK) cells have been extensively used in treatment of cancer patients in China. Clinical trials demonstrated that there were markedly decreased tumor nodules in size in a patient with advanced pancreatic adenocarcinoma following four cycles of CIK cell infusion and thus the patient had a longer progression-free survival. Moreover, immunotherapy with CIK cells in combination with chemotherapy had more potential benefits including longer progression-free survival and overall survival in patients with cancer such as advanced gastric cancer and non-small-cell lung cancer as compared with chemotherapy alone. In addition, dendritic cell (DC)-CIK cells have increased proliferation ability, cytokine secretion and anti-tumor activity as compared with CIK cells alone.

## Results

A clinical trial showed that immunotherapy with tumor lysate-pulsed DC-CIK cells could significantly increase overall survival rates than no treatment control in renal cancer carcinoma patients. Thus, nowadays, DC-CIK cells have also been extensively used in treatment of cancer patients in China although the efficacy and mechanisms of adoptive cell transfer therapy with DC-CIK cells remains to be determined. In one word, the accumulation of basic researches and clinical studies related to cancer immunotherapy with CIK and DC-CIK cells has confirmed their safety and feasibility in treating malignant diseases. However, at present, there are still no uniform criteria or large-scale preparations of CIK and DC-CIK cells and the overall clinical response is difficult to evaluate due to lack of practical and appropriate criteria.

## Conclusions

Large-scale, controlled, grouped, and multi-center clinical trials on CIK and DC-CIK cell-based immunotherapy should be conducted in the near future.

## Acknowledgements

Supported by "Taishan Scholar" special fund from Shandong Government, China.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P64

**Cite this article as:** Zhou: Recent advances in adoptive cancer immunotherapy in china. *Journal for ImmunoTherapy of Cancer* 2015 **3** (Suppl 2):P64.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)



Ludong University, Lexington, SC, USA



© 2015 Zhou This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.